2020
ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.
Ma C, Suman V, Leitch A, Sanati S, Vij K, Unzeitig G, Hoog J, Watson M, Hahn O, Guenther J, Caudle A, Dockter T, Korde L, Weiss A, Hunt K, Hudis C, Winer E, Partridge A, Carey L, Ellis M. ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106. Journal Of Clinical Oncology 2020, 38: 504-504. DOI: 10.1200/jco.2020.38.15_suppl.504.Peer-Reviewed Original ResearchHER2- BCEstrogen receptor-positive HER2-negative breast cancerClinical stage II/IIIBreast conservation surgery (BCS) ratesHER2-negative breast cancerRecurrence-free survival ratesStage II/IIIClinical stage IIPathologic complete responseWk 4Chi-square testAdjuvant chemotherapyCN1-3Neoadjuvant phasePrimary endpointAlone armPostmenopausal womenComplete responseLoading dosePM patientsBCS ratesSurgery ratesPO dailyBreast cancerLower risk
1992
High-Dose Oral Tamoxifen, a Potential Multidrug-Resistance-Reversal Agent: Phase I Trial in Combination With Vinblastine
Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL. High-Dose Oral Tamoxifen, a Potential Multidrug-Resistance-Reversal Agent: Phase I Trial in Combination With Vinblastine. Journal Of The National Cancer Institute 1992, 84: 1811-1816. PMID: 1359155, DOI: 10.1093/jnci/84.23.1811.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAntineoplastic Combined Chemotherapy ProtocolsATP Binding Cassette Transporter, Subfamily B, Member 1Drug Administration ScheduleDrug ResistanceFemaleHumansInfusions, IntravenousMaleMembrane GlycoproteinsMiddle AgedNeoplasm ProteinsNeoplasmsTamoxifenVinblastineConceptsLoading doseN-desmethyltamoxifenOral tamoxifenContinuous infusionPlasma concentrationsHigh-dose oral tamoxifenDose-limiting toxic effectPhase I clinical trialAdvanced epithelial tumorsHigh-dose tamoxifenTriphenylethylene antiestrogen tamoxifenPhase II trialDose-limiting toxicityPhase I trialDoses of tamoxifenStart of treatmentP-glycoprotein functionToxicity of vinblastineAnti-neoplastic agentsToxic effectsMetabolite N-desmethyltamoxifenIntracellular concentrationAsymptomatic prolongationStarting doseII trial